Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer

16 Sept 2024

Abstract excerpt

Non-small cell lung cancer (NSCLC) is a highly aggressive type of lung cancer with poor responses to traditional therapies such as surgery, radiotherapy, and chemotherapy. While immunotherapy has become an effective approach for treating multiple types of cancer, solid tumors frequently exhibit immune escape through various mechanisms, including downregulation of MHC I expression. However, whether the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cytokine Signaling Pathways and Interactions
Share to Effects of Radiation Exposure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39283477
DOI: 10.1007/s13402-024-00989-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancerPMID 39283477Read ↗

Low-dose SAHA enhances CD8+T cell-mediated antitumor immunity by upregulating MHC I expression in non-small cell lung cancersSemantic proximity Read ↗

Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.Semantic proximity Read ↗

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read ↗

A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung CancerSemantic proximity Read ↗

Differential Transcriptomic Modulation by Histone Deacetylase Inhibitor SAHA in LUAD and LUSCSemantic proximity Read ↗

HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung CancerSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancerSemantic proximity Read ↗

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cellsSemantic proximity Read ↗

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug OxaliplatinSemantic proximity Read ↗

Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.